Stuart H. Gold

Stuart H. Gold, MD, is a UNC Lineberger Comprehensive Cancer Center member and Professor and Chief in the Department of Pediatrics and Division of Pediatric Hematology-Oncology at UNC-Chapel Hill. Gold's procedure and research experience includes general pediatric hematology and oncology with special interest in leukemias, brain tumors, integrative medicine, late effects, long-term survivorship issues, and palliative care.

Stuart H. Gold

Professor; Chief, Division of Pediatric Hematology-Oncology
UNC-Chapel Hill
Clinical Research
Pediatric Hematology Oncology Program


Clinical profile

Area of interest

Dr. Gold is an accomplished clinical research specialist with special interests in acute leukemia's brain tumors and late effects of cancer therapy. With the assistance of Gwen Konsler, RN, Dr. Gold opened a late effects clinic to serve the needs of children long off treatment but at risk for late occurring side effects of their chemotherapy. Dr. Gold also heads a comprehensive brain tumor clinic that meets monthly. This clinic brings together experts from the disciplines of neurology, neurosurgery, radiology, psychology and sociology. Patients receive comprehensive, multidisciplinary evaluation, treatment planning and therapy. Dr. Gold also runs a monthly clinic in Wilmington and Raleigh that serves the pediatric oncology needs of those communities.

In addition to these responsibilities, Dr. Gold serves on multiple important cancer committees. Dr. Gold is a member of several key committees and treatment protocol committees in the Children's Cancer Group (CCG). The CCG is the largest group of Pediatric Cancer institutions in the world, which pools its resources and patients to advance the treatment outcomes for children with cancer. Dr. Gold also serves on several state committees and is an officer of the board of the Chapel Hill Ronald McDonald House.

Dr. Gold has completed a study of long-term survivors of childhood cancer. In collaboration with investigators at Duke University, he is the principle investigator of a phase I trial of an ara-G analogue for recurrent leukemia and lymphoma. He also continues laboratory investigations into gene amplification, particularly the ability of normal T and B-lymphocytes to amplify the CAD gene in leukemia.

Link to Publications on Reach NC site

Find publications on Pubmed